Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

Author's Avatar
May 31, 2022

Spruce+Biosciences%2C+Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104%3Csup%3Eth%3C%2Fsup%3E+Annual+Meeting+of+the+Endocrine+Society+%28ENDO+2022%29 taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent survey of individuals living with congenital adrenal hyperplasia (CAH) to assess their perceptions around glucocorticoid treatment regimens and glucocorticoid-associated side effects.